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0 Case Report 
ENHANCING MEDIASTINAL MASS AT MR: CASTLEMAN DISEASE 
MING LIN HSIEH, *l LESLIE E. QUINT, * JOHN M. FAUST,*~ AND JENNIFER E. TURNER~~ 
*Department of Radiology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA, and 
TDepartment of Radiology, University of Mississippi Medical Center, Jackson, MS 39216, USA 
We report a case of an enhancing middle mediastinal mass imaged by MR and CT. Repeated nondiagnostic biop- 
sies in this 25yr-old male patient had resulted in profuse hemorrhage. Final pathological diagnosis after thoracot- 
omy and debulking was Castleman disease. This is a rare, benign lymphoproliferative disorder of uncertain etiology. 
Histological varieties include the hyaline vascular type (8040%) and the plasma cell type (lo-20%). Cure is gen- 
erally accomplished via surgical excision. This entity should be included in the differential diagnosis of enhancing 
mediastinal lesions, prompting awareness of the potential for bleeding complications following biopsy. 
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Castleman disease is a rare, benign lymphoprolifera- 
tive disorder of uncertain etiology, as evidenced by the 
multiple synonyms of the disease, including angiofol- 
licular lymph node hyperplasia, lymphoid hamartoma, 
benign giant lymphoma, and follicular reticuloma. 
The majority of reported cases are solitary masses in 
the thorax, predominantly in the hila and mediasti- 
num.’ However, the disease can occur in extrathoracic 
lymph nodes, as well as in non-lymphoid tissues such 
as the central nervous system.’ Cure is generally ac- 
complished via surgical excision. Approximately 80- 
90% of cases are of the hyaline vascular histological 
type, and the remainder are of the plasma cell type. The 
latter type is often associated with systemic signs and 
symptoms, including fever, increased sedimentation 
rate, anemia, hyperglobulinemia, and leukocytosis.’ 
CT findings of several cases of Castleman disease have 
been previously described,374 however there is scant in- 
formation regarding MR imaging characteristics of this 
disease.5*6 We describe one case of mediastinal Castle- 
man disease imaged by CT and contrast enhanced MR. 
CASE REPORT 
An otherwise healthy 2%yr-old man presented with 
a several year history of recurrent pneumonias and re- 
cent hemoptysis unresponsive to antibiotic therapy. 
Chest radiographs revealed a right hilar mass and wid- 
ening of the carina, suggestive of a subcarinal mass. 
At bronchoscopy, there was a large submucosal mass 
at the carina as well as a submucosal and endobron- 
chial, friable mass that nearly occluded the right main- 
stem bronchus. Bronchoscopic washing, brushing, and 
biopsy led to copious bleeding; pathology was non- 
diagnostic. Subsequent contrast enhanced thoracic CT 
scanning demonstrated a 6 x 6 x 10 cm high attenua- 
tion, subcarinal mass which compressed the carina 
from below and encircled the right lower lobe bronchus 
(Fig. 1). The mass was fairly homogeneous except for 
multiple coarse calcifications. There were a few asso- 
ciated nonenlarged precarinal and right paratracheal 
lymph nodes. 
Thoracic MR imaging at 1.5 T was done using co- 
ronal ?-,-weighted and axial Tz-weighted images be- 
fore contrast, and axial T, -weighted images following 
intravenous (IV) administration of gadopentetate di- 
meglumine. Compared to muscle, the mass was slightly 
hyperintense at Tl -weighting and extremely hyperin- 
tense at T2-weighting, and it showed marked enhance- 
ment after contrast administration (Fig. 2). Lesion- 
to-fat signal intensity ratios were 0.93 on precontrast 
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Fig. 1. Contrast enhanced CT shows a high density subcar- 
inal mass (arrowheads) with central calcifications. The mass 
encases and possibly invades the bronchus intermedius 
(arrow). 
T, -weighted images, 1.05 on T,-weighted images, and 
0.93 on T, -weighted postcontrast images. Intratumoral 
calcifications seen at CT were difficult to appreciate 
at MR. 
Mediastinoscopy and mediastinotomy resulted in 
difficult hemostasis; tissue obtained was nondiagnos- 
tic. Subsequent thoracotomy revealed a large friable, 
highly vascular subcarinal mass that extended into the 
carina and was felt to be unresectable. The mass was 
debulked and frozen section tissue analysis reported 
possible Hodgkin disease. The final pathological re- 
port, after routine histological and electron microscopic 
analysis, was plasma cell variant of Castleman disease. 
Postoperative bone marrow biopsy and abdominal CT 
scan were negative. Given the unresectable nature of 
the mass, the patient was treated with radiation ther- 
apy (3600 centigray) to the mediastinum. This resulted 
in at least 75% reduction in tumor mass at MR. Lesion- 
Fig. 2. Pre- and postcontrast MR images at 1.5 T. (A) Cor- 
onal T,-weighted (SE 700/20) image demonstrates widening 
of the carina and possible occlusion of the bronchus inter- 
medius and proximal right lower lobe bronchus by the large 
mass (arrows). Central calcifications are not identified. (B) 
The mass (arrows) is markedly hyperintense on axial T,- 
weighted images (SE 2500/80). (C) Prominent enhancement 
is seen after administration of gadolinium (T, -weighted; SE 
800/72). 
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to-fat signal intensity ratios after radiation therapy were 
0.77 on precontrast T,-weighted images and 0.96 on 
Tz-weighted images. Contrast enhanced images were 
not obtained at this time. Thirteen months following 
surgery, the patient was asymptomatic. 
DISCUSSION 
The CT findings in this case agree with the typical 
findings described in the literature for this disease en- 
tity, that is, a well-defined, solitary mass with homo- 
geneous, intense contrast enhancement and scattered, 
dense calcifications, as weII as small adjacent lymph 
nodes.‘*3v4 
To our knowledge, there are only two prior cases of 
chest or abdominal Castleman disease that have been 
imaged with MR and reported in the literature; neither 
of these cases used IV contrast.5*6 De Geer at al. de- 
scribed one patient with mediastinal hyaline vascular 
type Castleman disease imaged at 0.35T.5 The mass/fat 
ratio was 0.50 at T,-weighting and 0.77 at T,-weight- 
ing. The mass did not show significant contrast enhance- 
ment at CT. A case of retroperitoneal Castleman disease 
reported by Bartkowski and Ferrigni was isointense 
with muscle at T, -weighting and nearly isointense with 
fat at T2-weighting; calcification and contrast enhance- 
ment were present at CT.6 Our case showed similar 
MR imaging characteristics. In addition, hypervascu- 
larity of the tumor was confirmed via marked enhance- 
ment after administration of gadolinium. 
Advantages of MR over CT in this setting include 
the capability to perform multiplanar imaging; this may 
be extremely useful in surgical or radiation therapy 
treatment planning. Moreover, in patients with contra- 
indications to IV urographic contrast (e.g., renal fail- 
ure or prior contrast reaction), tumor enhancement can 
be assessed using contrast enhanced MR. One advan- 
tage of CT is the ability to detect intratumoral calcifi- 
cations; the presence of such calcifications may aid in 
the differential diagnosis. 
The differential diagnosis of an isolated subcari- 
nal mass is long; enhancement of the lesion would be 
consistent with paraganglioma, carcinoid, aneurysm, 
lymph node enlargement due to metastasis from hyper- 
vascular primary tumors, parathyroid tumors, or ec- 
topic thyroid. The presence of calcifications favors 
paraganglioma, carcinoid, aneurysm, or ectopic thy- 
roid. Lymphomas do not typically show strong contrast 
enhancement at CT,’ and calcification would be un- 
usual in an untreated lymphoma. The morphology of 
the lesion, the pattern of calcification, the degree of 
contrast enhancement and the lack of flow void ex- 
clude the diagnosis of aneurysm in our case. Ectopic 
thyroid would not invade the tracheobronchial tree. 
The imaging features of this lesion are compatible with 
mediastinal carcinoid or paraganglioma, and silent en- 
docrine tumors of these types could not have been 
excluded. 
Profuse hemorrhage that occurred during tissue 
sampling in our case is not uncommon in Castleman 
disease, and pre-resection embolization has been used 
in some cases.8 It is important to include Castleman 
disease in the differential diagnosis of enhancing me- 
diastinal lesions, in order to alert the surgeon to the 
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